Ventyx Biosciences, Inc. (VTYX)

US — Healthcare Sector
Peers: ACLX  IMCR  PCVX  DICE  NUVL  CERE  TVTX  GPCR    REPL  ASND  UTHR  IDYA  PTGX  VRNA  SNDX 

Automate Your Wheel Strategy on VTYX

With Tiblio's Option Bot, you can configure your own wheel strategy including VTYX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VTYX
  • Rev/Share 0.0
  • Book/Share 3.2564
  • PB 0.5558
  • Debt/Equity 0.0455
  • CurrentRatio 19.5706
  • ROIC -0.5648

 

  • MktCap 128801772.0
  • FreeCF/Share -1.533
  • PFCF -1.1811
  • PE -1.0384
  • Debt/Assets 0.0416
  • DivYield 0
  • ROE -0.4745

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
VTYX
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's …

Read More
image for news Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

About Ventyx Biosciences, Inc. (VTYX)

  • IPO Date 2021-10-21
  • Website https://www.ventyxbio.com
  • Industry Biotechnology
  • CEO Dr. Raju S. Mohan Ph.D.
  • Employees 81
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.